2018 Q3 Form 10-K Financial Statement
#000114420418049866 Filed on September 18, 2018
Income Statement
| Concept | 2018 Q3 | 2018 | 2017 Q2 |
|---|---|---|---|
| Revenue | $45.00K | $444.0K | $150.0K |
| YoY Change | -63.11% | 12.69% | -46.43% |
| Cost Of Revenue | |||
| YoY Change | |||
| Gross Profit | |||
| YoY Change | |||
| Gross Profit Margin | |||
| Selling, General & Admin | $2.871M | $10.34M | $2.890M |
| YoY Change | 14.84% | -1.96% | 32.57% |
| % of Gross Profit | |||
| Research & Development | $1.124M | $3.986M | $1.110M |
| YoY Change | 14.11% | -3.18% | 30.59% |
| % of Gross Profit | |||
| Depreciation & Amortization | $360.0K | $1.368M | $430.0K |
| YoY Change | 6.51% | 3.17% | 4.88% |
| % of Gross Profit | |||
| Operating Expenses | $3.995M | $14.67M | $4.010M |
| YoY Change | 14.7% | 0.02% | 32.34% |
| Operating Profit | -$3.950M | -$14.23M | |
| YoY Change | 17.52% | -0.33% | |
| Interest Expense | $476.0K | $1.915M | -$480.0K |
| YoY Change | -0.83% | -0.73% | 2.13% |
| % of Operating Profit | |||
| Other Income/Expense, Net | -$449.0K | -$1.881M | $10.00K |
| YoY Change | -3.65% | 0.86% | |
| Pretax Income | -$4.399M | -$16.11M | -$4.330M |
| YoY Change | 14.86% | -0.19% | 34.47% |
| Income Tax | $0.00 | ||
| % Of Pretax Income | |||
| Net Earnings | -$4.398M | -$16.11M | -$4.330M |
| YoY Change | 14.95% | 10.82% | 61.57% |
| Net Earnings / Revenue | -9773.33% | -3627.25% | -2886.67% |
| Basic Earnings Per Share | |||
| Diluted Earnings Per Share | -$245.8K | -$1.515M | -$486.0K |
| COMMON SHARES | |||
| Basic Shares Outstanding | 18.34M shares | 89.12M shares | |
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2018 Q3 | 2018 | 2017 Q2 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $16.01M | $15.93M | $8.090M |
| YoY Change | 170.44% | 97.01% | -64.84% |
| Cash & Equivalents | $16.01M | $8.088M | |
| Short-Term Investments | |||
| Other Short-Term Assets | $206.0K | $276.0K | $280.0K |
| YoY Change | -1.9% | -2.47% | 7.69% |
| Inventory | $0.00 | $30.00K | |
| Prepaid Expenses | |||
| Receivables | $119.0K | $75.00K | $175.0K |
| Other Receivables | $0.00 | $0.00 | $0.00 |
| Total Short-Term Assets | $16.34M | $16.29M | $8.572M |
| YoY Change | 156.03% | 89.98% | -64.14% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $24.98M | $25.15M | $25.59M |
| YoY Change | -1.14% | -1.71% | 0.06% |
| Goodwill | |||
| YoY Change | |||
| Intangibles | $1.554M | $1.823M | |
| YoY Change | -11.55% | -12.86% | |
| Long-Term Investments | |||
| YoY Change | |||
| Other Assets | $26.00K | $26.00K | $30.00K |
| YoY Change | -13.33% | 0.0% | 0.0% |
| Total Long-Term Assets | $26.56M | $26.80M | $27.44M |
| YoY Change | -1.82% | -2.33% | -0.92% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $16.34M | $16.29M | $8.572M |
| Total Long-Term Assets | $26.56M | $26.80M | $27.44M |
| Total Assets | $42.90M | $43.08M | $36.01M |
| YoY Change | 28.3% | 19.64% | -30.21% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $692.0K | $790.0K | $749.0K |
| YoY Change | 15.33% | 5.47% | -36.36% |
| Accrued Expenses | $1.125M | $1.048M | $924.0K |
| YoY Change | 7.14% | 13.42% | 0.43% |
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | $201.0K | $197.0K | $180.0K |
| YoY Change | 5.79% | 7.65% | 5.88% |
| Total Short-Term Liabilities | $5.036M | $2.035M | $2.013M |
| YoY Change | 138.67% | 1.09% | -12.13% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $24.83M | $24.88M | $25.08M |
| YoY Change | -0.79% | -0.79% | -0.75% |
| Other Long-Term Liabilities | |||
| YoY Change | |||
| Total Long-Term Liabilities | $24.83M | $24.88M | $25.08M |
| YoY Change | -0.79% | -0.79% | -0.75% |
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $5.036M | $2.035M | $2.013M |
| Total Long-Term Liabilities | $24.83M | $24.88M | $25.08M |
| Total Liabilities | $29.87M | $26.92M | $27.10M |
| YoY Change | 10.05% | -0.66% | -1.67% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$92.63M | -$72.12M | |
| YoY Change | 25.23% | ||
| Common Stock | $105.7M | $81.07M | |
| YoY Change | 20.0% | ||
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | $13.03M | $16.17M | $8.914M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $42.90M | $43.08M | $36.01M |
| YoY Change | 28.32% | 19.64% | -30.21% |
Cashflow Statement
| Concept | 2018 Q3 | 2018 | 2017 Q2 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$4.398M | -$16.11M | -$4.330M |
| YoY Change | 14.95% | 10.82% | 61.57% |
| Depreciation, Depletion And Amortization | $360.0K | $1.368M | $430.0K |
| YoY Change | 6.51% | 3.17% | 4.88% |
| Cash From Operating Activities | -$778.0K | -$13.48M | -$3.760M |
| YoY Change | -74.21% | 2.41% | 33.33% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | $274.0K | $934.0K | -$520.0K |
| YoY Change | 185.42% | -29.4% | 766.67% |
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | |||
| YoY Change | |||
| Cash From Investing Activities | -$289.0K | -$1.079M | -$520.0K |
| YoY Change | 160.36% | -32.27% | 766.67% |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | $1.350M | ||
| YoY Change | 35.0% | ||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | $1.143M | $22.41M | -40.00K |
| YoY Change | 19.56% | -13280.0% | -101.0% |
| NET CHANGE | |||
| Cash From Operating Activities | -$778.0K | -$13.48M | -3.760M |
| Cash From Investing Activities | -$289.0K | -$1.079M | -520.0K |
| Cash From Financing Activities | $1.143M | $22.41M | -40.00K |
| Net Change In Cash | $76.00K | $7.847M | -4.320M |
| YoY Change | -103.5% | -152.57% | -485.71% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$778.0K | -$13.48M | -$3.760M |
| Capital Expenditures | $274.0K | $934.0K | -$520.0K |
| Free Cash Flow | -$1.052M | -$14.41M | -$3.240M |
| YoY Change | -66.21% | -0.5% | 17.39% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2018 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<div style="text-align:left;"><table style="border: none; border-collapse: collapse; margin-bottom: 0.001pt; width: 100%; table-layout: fixed;"><tr><td style="border-width: initial; border-style: none; border-color: initial; padding: 0px; vertical-align: top; width: 0.3pt;"></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: top;width: 18pt;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1.</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: top;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: justify; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nature of Business</div></div></div></td></tr></table></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"><div style="font-family: "times new roman", serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">iBio, Inc. and Subsidiaries (“iBio” or the “Company”) is a biotechnology company focused on using our proprietary technologies and production facilities to provide product development and manufacturing services to clients, collaborators and third-party customers as well as developing and commercializing our own product candidates.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"><div style="font-family: "times new roman", serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">iBio was established as a public company in August 2008 as the result of a spinoff from Integrated BioPharma, Inc. The Company operates in one business segment under the direction of its Executive Chairman. The Company’s wholly-owned and majority-owned subsidiaries are as follows:</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-left: 0.50in;margin-top: 0;text-align: justify;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">iBio CDMO LLC</div> (“iBio CDMO”) (originally named iBio CMO LLC) – iBio CDMO is a Delaware limited liability company formed on December 16, 2015 as iBio CMO, LLC to develop and manufacture plant-made pharmaceuticals. Effective July 1, 2017, iBio CMO changed its name to iBio CDMO. As of December 31, 2015, the Company owned 100% of iBio CDMO. On January 13, 2016, the Company entered into a contract manufacturing joint venture with an affiliate of Eastern Capital Limited (“Eastern”), a stockholder of the Company (the “Eastern Affiliate”). The Eastern Affiliate contributed $15 million in cash for a 30% interest in iBio CDMO. The Company retained a 70% interest in iBio CDMO and contributed a royalty-bearing license which grants iBio CDMO a non-exclusive license to use the Company’s proprietary technologies for research purposes and an exclusive U.S. license for manufacturing purposes. The Company retained the exclusive right to grant product licenses to those who wish to sell or distribute products made using the Company’s technologies.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-left: 0.5in; margin-top: 0px; text-align: justify; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-left: 0.50in;margin-top: 0;text-align: justify;"><div style="font-family: "times new roman", serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On February 23, 2017, the Company entered into an exchange agreement with the Eastern Affiliate, pursuant to which the Company acquired substantially all of the interest in iBio CDMO held by the Eastern Affiliate in exchange for one share of the Company’s iBio CMO Preferred Tracking Stock, par value $0.001 per share. After giving effect to the transaction, the Company owns 99.99% of iBio CDMO. See Note 11 for a further discussion.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-left: 0.5in; margin-top: 0px; text-align: justify; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-left: 0.50in;margin-top: 0;text-align: justify;"><div style="font-family: "times new roman", serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">iBio CDMO’s operations take place in Bryan, Texas in a facility controlled by another affiliate of Eastern (the “Second Eastern Affiliate”) as sublandlord. The facility is a 139,000-square foot Class A life sciences building located on land owned by the Texas A&M system, designed and equipped for plant-made manufacture of biopharmaceuticals. The Second Eastern Affiliate granted iBio CDMO a 34-year capital lease for the facility as well as certain equipment (see Note 10). Commercial operations commenced in January 2016. iBio CDMO expects to operate on the basis of three parallel lines of business: (1) Development and manufacturing of third-party products; (2) Development and production of iBio’s proprietary product(s) for treatment of fibrotic diseases and/or other proprietary iBio products; and (3) Commercial technology transfer services including facility design, as needed.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-left: 0.5in; margin-top: 0px; text-align: justify; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-left: 0.50in;margin-top: 0;text-align: justify;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">iBIO DO BRASIL BIOFARMACÊUTICA LTDA</div> (“iBio Brazil”) – iBio Brazil is a subsidiary organized in Brazil in which the Company has a 99% interest. iBio Brazil was formed to manage and expand the Company’s business activities in Brazil. The activities of iBio Brazil are intended to include coordination and expansion of the Company’s existing relationship with Fundacao Oswaldo Cruz/Fiocruz (“Fiocruz”) beyond the current Yellow Fever Vaccine program (see Note 8) and development of additional products with private sector participants for the Brazilian market. iBio Brazil commenced operations during the first quarter of the fiscal year ended June 30, 2015.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-left: 0.5in; margin-top: 0px; text-align: justify; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-left: 0.50in;margin-top: 0;text-align: justify;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">iBio Manufacturing LLC</div> (“iBio Manufacturing”) – iBio Manufacturing, a wholly-owned subsidiary, is a Delaware limited liability company formed in November 2015. iBio Manufacturing has not commenced any activities to date.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> | |
| CY2018 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"><div style="font-family: "times new roman", serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates</div></div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"><div style="font-family: "times new roman", serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates include the valuation of intellectual property, legal and contractual contingencies and share-based compensation. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> | |
| CY2017Q2 | us-gaap |
Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
|
87000 | USD |
| CY2018 | us-gaap |
Revenues
Revenues
|
444000 | USD |
| CY2017 | us-gaap |
Revenues
Revenues
|
394000 | USD |
| CY2018 | us-gaap |
Capital Leases Income Statement Interest Expense
CapitalLeasesIncomeStatementInterestExpense
|
1915000 | USD |
| CY2017 | us-gaap |
Capital Leases Income Statement Interest Expense
CapitalLeasesIncomeStatementInterestExpense
|
1928000 | USD |
| CY2016Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
1227333 | shares |
| CY2017 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
158500 | shares |
| CY2018 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
21000 | shares |
| CY2018 | ibio |
Sub Lease Expiration Period
SubLeaseExpirationPeriod
|
P34Y | |
| CY2018 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-16105000 | USD |
| CY2017 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-14532000 | USD |
| CY2018 | us-gaap |
Profit Loss
ProfitLoss
|
-16108000 | USD |
| CY2017 | us-gaap |
Profit Loss
ProfitLoss
|
-16139000 | USD |
| CY2018Q2 | us-gaap |
Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
|
189000 | USD |
| CY2018 | dei |
Amendment Flag
AmendmentFlag
|
false | |
| CY2017Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
1354833 | shares |
| CY2018 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0 | pure |
| CY2018Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
1364583 | shares |
| CY2017 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0 | pure |
| CY2018 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
3986000 | USD |
| CY2017 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
4117000 | USD |
| CY2018Q2 | us-gaap |
Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
|
5584000 | USD |
| CY2017Q2 | us-gaap |
Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
|
5446000 | USD |
| CY2018 | us-gaap |
Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
|
877000 | USD |
| CY2017 | us-gaap |
Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
|
957000 | USD |
| CY2018 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
770000 | USD |
| CY2017 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
1010000 | USD |
| CY2018 | us-gaap |
Dividends Preferred Stock Stock
DividendsPreferredStockStock
|
260000 | USD |
| CY2017 | us-gaap |
Dividends Preferred Stock Stock
DividendsPreferredStockStock
|
90000 | USD |
| CY2018 | us-gaap |
Lease And Rental Expense
LeaseAndRentalExpense
|
2100000 | USD |
| CY2018 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
11250 | shares |
| CY2017 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
31000 | shares |
| CY2018 | dei |
Document Type
DocumentType
|
10-K | |
| CY2018 | ibio |
Capital Lease Obligation Description
CapitalLeaseObligationDescription
|
the base rent, iBio CDMO is required to pay, for each calendar year during the term, a portion of the total gross sales for products manufactured or processed at the facility, equal to 7% of the first $5,000,000 of gross sales, 6% of gross sales between $5,000,001 and $25,000,000, 5% of gross sales between $25,000,001 and $50,000,000, 4% of gross sales between $50,000,001 and $100,000,000, and 3% of gross sales between $100,000,001 and $500,000,000. However, if for any calendar year period from January 1, 2018 through December 31, 2019, iBio CDMO's applicable gross sales are less than $5,000,000, or for any calendar year period from and after January 1, 2020, its applicable gross sales are less than $10,000,000, then iBio CDMO is required to pay the amount that would have been payable if it had achieved such minimum gross sales and shall pay no less than the applicable percentage for the minimum gross sales for each subsequent calendar year. Percentage rent amounted to $199,000 and $107,000 in 2018 and 2017, respectively. | |
| CY2018 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-16365000 | USD |
| CY2017 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-14622000 | USD |
| CY2017 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.35 | pure |
| CY2018 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
770000 | USD |
| CY2017 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
1010000 | USD |
| CY2018Q2 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
3964000 | USD |
| CY2017Q2 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
3623000 | USD |
| CY2018 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
10685000 | USD |
| CY2017 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
10551000 | USD |
| CY2018Q2 | us-gaap |
Due To Related Parties Current
DueToRelatedPartiesCurrent
|
789000 | USD |
| CY2017Q2 | us-gaap |
Due To Related Parties Current
DueToRelatedPartiesCurrent
|
650000 | USD |
| CY2018Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
15934000 | USD |
| CY2017Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
8088000 | USD |
| CY2018 | us-gaap |
Operating Expenses
OperatingExpenses
|
14671000 | USD |
| CY2017 | us-gaap |
Operating Expenses
OperatingExpenses
|
14668000 | USD |
| CY2018Q2 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
1620000 | USD |
| CY2017Q2 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
1823000 | USD |
| CY2018 | us-gaap |
Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party
RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
|
942000 | USD |
| CY2017 | us-gaap |
Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party
RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
|
775000 | USD |
| CY2018 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
341000 | USD |
| CY2017 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
350000 | USD |
| CY2018Q2 | us-gaap |
Capital Leases Future Minimum Payments Due Current
CapitalLeasesFutureMinimumPaymentsDueCurrent
|
2100000 | USD |
| CY2018Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
|
1362221 | shares |
| CY2018 | dei |
Document Period End Date
DocumentPeriodEndDate
|
2018-06-30 | |
| CY2018 | dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2018 | |
| CY2017 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
|
1.031 | pure |
| CY2018 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
|
1.03 | pure |
| CY2018Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
1144754 | shares |
| CY2018Q2 | us-gaap |
Capital Leases Future Minimum Payments Due In Two Years
CapitalLeasesFutureMinimumPaymentsDueInTwoYears
|
2100000 | USD |
| CY2018 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
10631000 | shares |
| CY2017 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
8911000 | shares |
| CY2018 | us-gaap |
Depreciation
Depreciation
|
1368000 | USD |
| CY2017 | us-gaap |
Depreciation
Depreciation
|
1326000 | USD |
| CY2018 | us-gaap |
Interest Expense Related Party
InterestExpenseRelatedParty
|
1915000 | USD |
| CY2017 | us-gaap |
Interest Expense Related Party
InterestExpenseRelatedParty
|
1928000 | USD |
| CY2018 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-14227000 | USD |
| CY2017 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-14274000 | USD |
| CY2018Q2 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
75000 | USD |
| CY2017Q2 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
175000 | USD |
| CY2018Q2 | us-gaap |
Inventory Work In Process
InventoryWorkInProcess
|
0 | USD |
| CY2017Q2 | us-gaap |
Inventory Work In Process
InventoryWorkInProcess
|
26000 | USD |
| CY2018 | us-gaap |
Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
|
P10Y | |
| CY2018 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-1.54 | |
| CY2017 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-1.64 | |
| CY2018Q2 | us-gaap |
Capital Leases Future Minimum Payments Due In Three Years
CapitalLeasesFutureMinimumPaymentsDueInThreeYears
|
2100000 | USD |
| CY2016Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
13.10 | |
| CY2018 | dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
FY | |
| CY2018 | us-gaap |
Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
|
61000 | USD |
| CY2017 | us-gaap |
Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
|
0 | USD |
| CY2018 | dei |
Entity Registrant Name
EntityRegistrantName
|
iBio, Inc. | |
| CY2017 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
4.00 | |
| CY2018 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
3.12 | |
| CY2018Q2 | us-gaap |
Capital Leases Future Minimum Payments Due In Four Years
CapitalLeasesFutureMinimumPaymentsDueInFourYears
|
2100000 | USD |
| CY2018 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-39000 | USD |
| CY2017 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-309000 | USD |
| CY2018 | us-gaap |
Interest Expense
InterestExpense
|
1915000 | USD |
| CY2017 | us-gaap |
Interest Expense
InterestExpense
|
1929000 | USD |
| CY2018Q2 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
276000 | USD |
| CY2017Q2 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
283000 | USD |
| CY2018 | ibio |
Revenues From Grants
RevenuesFromGrants
|
44000 | USD |
| CY2017 | ibio |
Revenues From Grants
RevenuesFromGrants
|
131000 | USD |
| CY2018Q2 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2017Q2 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2018Q2 | us-gaap |
Assets Current
AssetsCurrent
|
16285000 | USD |
| CY2017Q2 | us-gaap |
Assets Current
AssetsCurrent
|
8572000 | USD |
| CY2018 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
15000 | USD |
| CY2017 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
39000 | USD |
| CY2018Q2 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
28424000 | USD |
| CY2017Q2 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
27493000 | USD |
| CY2018 | us-gaap |
Increase Decrease In Unbilled Receivables
IncreaseDecreaseInUnbilledReceivables
|
0 | USD |
| CY2017 | us-gaap |
Increase Decrease In Unbilled Receivables
IncreaseDecreaseInUnbilledReceivables
|
-122000 | USD |
| CY2018Q2 | us-gaap |
Capital Leases Future Minimum Payments Due In Five Years
CapitalLeasesFutureMinimumPaymentsDueInFiveYears
|
2100000 | USD |
| CY2018 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
4.00 | |
| CY2017 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
11.11 | |
| CY2018 | dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001420720 | |
| CY2018 | dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--06-30 | |
| CY2017Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
12.08 | |
| CY2018Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
12.01 | |
| CY2018Q2 | us-gaap |
Capital Leases Future Minimum Payments Due Thereafter
CapitalLeasesFutureMinimumPaymentsDueThereafter
|
56175000 | USD |
| CY2018 | us-gaap |
Increase Decrease In Finished Goods And Work In Process Inventories
IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories
|
-26000 | USD |
| CY2017 | us-gaap |
Increase Decrease In Finished Goods And Work In Process Inventories
IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories
|
4000 | USD |
| CY2018Q2 | us-gaap |
Capital Leases Lessee Balance Sheet Assets By Major Class Accumulated Deprecation
CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation
|
3027000 | USD |
| CY2017Q2 | us-gaap |
Capital Leases Lessee Balance Sheet Assets By Major Class Accumulated Deprecation
CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation
|
1805000 | USD |
| CY2018 | us-gaap |
Royalty Income Nonoperating
RoyaltyIncomeNonoperating
|
19000 | USD |
| CY2017 | us-gaap |
Royalty Income Nonoperating
RoyaltyIncomeNonoperating
|
25000 | USD |
| CY2018Q2 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
25152000 | USD |
| CY2017Q2 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
25589000 | USD |
| CY2018Q2 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
275000000 | shares |
| CY2017Q2 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
175000000 | shares |
| CY2018Q2 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
16040126 | shares |
| CY2017Q2 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
8911851 | shares |
| CY2018Q2 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
1620000 | USD |
| CY2017Q2 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
1823000 | USD |
| CY2018 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-1881000 | USD |
| CY2017 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-1865000 | USD |
| CY2018Q2 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Excluding Capital Leased Assets
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentExcludingCapitalLeasedAssets
|
245000 | USD |
| CY2017Q2 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Excluding Capital Leased Assets
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentExcludingCapitalLeasedAssets
|
99000 | USD |
| CY2018 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-8000 | USD |
| CY2017 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
19000 | USD |
| CY2018Q2 | us-gaap |
Capital Leases Future Minimum Payments Due
CapitalLeasesFutureMinimumPaymentsDue
|
66675000 | USD |
| CY2018Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
|
12.01 | |
| CY2016Q2 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
24044000 | USD |
| CY2017Q2 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
8915000 | USD |
| CY2018 | dei |
Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
|
No | |
| CY2018 | dei |
Entity Voluntary Filers
EntityVoluntaryFilers
|
No | |
| CY2018Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
12.59 | |
| CY2018 | ibio |
Revenue From Intersegment
RevenueFromIntersegment
|
0 | USD |
| CY2017 | ibio |
Revenue From Intersegment
RevenueFromIntersegment
|
0 | USD |
| CY2018 | us-gaap |
Increase Decrease In Security Deposits
IncreaseDecreaseInSecurityDeposits
|
0 | USD |
| CY2017 | us-gaap |
Increase Decrease In Security Deposits
IncreaseDecreaseInSecurityDeposits
|
2000 | USD |
| CY2018Q2 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
3272000 | USD |
| CY2017Q2 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
1904000 | USD |
| CY2018Q2 | us-gaap |
Security Deposit
SecurityDeposit
|
26000 | USD |
| CY2017Q2 | us-gaap |
Security Deposit
SecurityDeposit
|
26000 | USD |
| CY2018Q2 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
16040126 | shares |
| CY2017Q2 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
8911851 | shares |
| CY2018Q2 | us-gaap |
Assets
Assets
|
43083000 | USD |
| CY2017Q2 | us-gaap |
Assets
Assets
|
36010000 | USD |
| CY2018 | us-gaap |
Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
|
-3000 | USD |
| CY2017 | us-gaap |
Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
|
-1607000 | USD |
| CY2018 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
49000 | USD |
| CY2017Q2 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
924000 | USD |
| CY2017 | us-gaap |
Interest And Other Income
InterestAndOtherIncome
|
64000 | USD |
| CY2018 | us-gaap |
Interest And Other Income
InterestAndOtherIncome
|
34000 | USD |
| CY2017 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-257000 | USD |
| CY2016 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P6Y4M24D | |
| CY2017 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P5Y10M24D | |
| CY2018 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P4Y10M24D | |
| CY2018 | dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | |
| CY2017 | ibio |
Stock Issued During Period Value Reverse Stock Splits
StockIssuedDuringPeriodValueReverseStockSplits
|
0 | USD |
| CY2018 | dei |
Entity Filer Category
EntityFilerCategory
|
Smaller Reporting Company | |
| CY2018 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
|
P4Y10M24D | |
| CY2018 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
124000 | USD |
| CY2017 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
4000 | USD |
| CY2018 | us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
-158000 | USD |
| CY2017 | us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
133000 | USD |
| CY2018 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
|
P4Y3M18D | |
| CY2017Q4 | dei |
Entity Public Float
EntityPublicFloat
|
12041281 | USD |
| CY2017 | us-gaap |
Noncontrolling Interest Increase From Business Combination
NoncontrollingInterestIncreaseFromBusinessCombination
|
0 | USD |
| CY2018 | dei |
Trading Symbol
TradingSymbol
|
IBIO | |
| CY2018Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
0 | USD |
| CY2017Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
138000 | USD |
| CY2016Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
993000 | USD |
| CY2018 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
2.77 | |
| CY2017 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
0.36 | |
| CY2018 | ibio |
Stock Issued During Period Value Common Stock
StockIssuedDuringPeriodValueCommonStock
|
9536000 | USD |
| CY2018 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-13480000 | USD |
| CY2017 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-13163000 | USD |
| CY2018Q2 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
790000 | USD |
| CY2017Q2 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
749000 | USD |
| CY2018Q2 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
1048000 | USD |
| CY2018Q2 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
|
372000 | USD |
| CY2018Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
|
0 | USD |
| CY2018Q3 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
18336792 | shares |
| CY2018 | us-gaap |
Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
|
-16109000 | USD |
| CY2017 | us-gaap |
Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
|
-16139000 | USD |
| CY2018 | ibio |
Stock Issued During Period Value Preferred Stock
StockIssuedDuringPeriodValuePreferredStock
|
12085000 | USD |
| CY2018Q2 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
|
0 | USD |
| CY2018 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
|
P1Y7M6D | |
| CY2018 | us-gaap |
Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
|
145000 | USD |
| CY2017 | us-gaap |
Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
|
270000 | USD |
| CY2018Q2 | us-gaap |
Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
|
197000 | USD |
| CY2017Q2 | us-gaap |
Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
|
183000 | USD |
| CY2018Q2 | us-gaap |
Deferred Revenue
DeferredRevenue
|
0 | USD |
| CY2017Q2 | us-gaap |
Deferred Revenue
DeferredRevenue
|
157000 | USD |
| CY2018 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
934000 | USD |
| CY2017 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
1323000 | USD |
| CY2017Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
15000 | shares |
| CY2018 | us-gaap |
Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
|
1175000 | USD |
| CY2018 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-1079000 | USD |
| CY2017 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-1593000 | USD |
| CY2018Q2 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
2035000 | USD |
| CY2017Q2 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
2013000 | USD |
| CY2018Q3 | us-gaap |
Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
|
1500000 | shares |
| CY2018Q2 | us-gaap |
Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
|
24884000 | USD |
| CY2017Q2 | us-gaap |
Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
|
25082000 | USD |
| CY2018Q2 | us-gaap |
Royalty Guarantees Commitments Amount
RoyaltyGuaranteesCommitmentsAmount
|
200000 | USD |
| CY2018 | us-gaap |
Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
|
0 | USD |
| CY2018 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Other Increases Decreases In Period Description
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodDescription
|
Plan was amended to increase the number of shares reserved for awards under the Plan from 1 million to 1.5 million. | |
| CY2018 | ibio |
Proceeds From Issuance Of Preferred And Common Stock
ProceedsFromIssuanceOfPreferredAndCommonStock
|
21621000 | USD |
| CY2017 | ibio |
Proceeds From Issuance Of Preferred And Common Stock
ProceedsFromIssuanceOfPreferredAndCommonStock
|
0 | USD |
| CY2018Q2 | us-gaap |
Liabilities
Liabilities
|
26919000 | USD |
| CY2017Q2 | us-gaap |
Liabilities
Liabilities
|
27095000 | USD |
| CY2018Q2 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
USD | |
| CY2017Q2 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
USD | |
| CY2018 | us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
1175000 | USD |
| CY2017 | us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
0 | USD |
| CY2018 | ibio |
Long Term Purchase Commitment Expire Date
LongTermPurchaseCommitmentExpireDate
|
2015-12-31 | |
| CY2018 | us-gaap |
Proceeds From Minority Shareholders
ProceedsFromMinorityShareholders
|
1050000 | USD |
| CY2017 | us-gaap |
Proceeds From Minority Shareholders
ProceedsFromMinorityShareholders
|
0 | USD |
| CY2018 | us-gaap |
Proceeds From Contributed Capital
ProceedsFromContributedCapital
|
1093000 | USD |
| CY2017 | us-gaap |
Proceeds From Contributed Capital
ProceedsFromContributedCapital
|
0 | USD |
| CY2018 | us-gaap |
Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
|
183000 | USD |
| CY2017 | us-gaap |
Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
|
170000 | USD |
| CY2018Q2 | us-gaap |
Common Stock Value
CommonStockValue
|
16000 | USD |
| CY2017Q2 | us-gaap |
Common Stock Value
CommonStockValue
|
9000 | USD |
| CY2018 | us-gaap |
Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
|
-1000 | USD |
| CY2017 | us-gaap |
Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
|
0 | USD |
| CY2018 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
7846000 | USD |
| CY2017 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-14926000 | USD |
| CY2018Q2 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
104408000 | USD |
| CY2017Q2 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
81057000 | USD |
| CY2018Q2 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-30000 | USD |
| CY2017Q2 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-29000 | USD |
| CY2016Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
23014000 | USD |
| CY2018Q2 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-88228000 | USD |
| CY2017Q2 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-72123000 | USD |
| CY2017Q1 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
1000000 | shares |
| CY2018Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
16166000 | USD |
| CY2017Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
8914000 | USD |
| CY2018Q2 | us-gaap |
Minority Interest
MinorityInterest
|
-2000 | USD |
| CY2017Q2 | us-gaap |
Minority Interest
MinorityInterest
|
1000 | USD |
| CY2017Q3 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
120000 | shares |
| CY2018 | ibio |
Unpaid Intangible Assets Included In Accounts Payable
UnpaidIntangibleAssetsIncludedInAccountsPayable
|
2000 | USD |
| CY2017 | ibio |
Unpaid Intangible Assets Included In Accounts Payable
UnpaidIntangibleAssetsIncludedInAccountsPayable
|
7000 | USD |
| CY2018 | ibio |
Capital Expenditure Incurred For Intangible Assets Paid
CapitalExpenditureIncurredForIntangibleAssetsPaid
|
7000 | USD |
| CY2017 | ibio |
Capital Expenditure Incurred For Intangible Assets Paid
CapitalExpenditureIncurredForIntangibleAssetsPaid
|
0 | USD |
| CY2018Q2 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
16164000 | USD |
| CY2018Q2 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
43083000 | USD |
| CY2017Q2 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
36010000 | USD |
| CY2018 | ibio |
Unpaid Fixed Assets Included In Accounts Payable
UnpaidFixedAssetsIncludedInAccountsPayable
|
84000 | USD |
| CY2017 | ibio |
Unpaid Fixed Assets Included In Accounts Payable
UnpaidFixedAssetsIncludedInAccountsPayable
|
87000 | USD |
| CY2018 | ibio |
Capital Expenditures Incurred Payments Made
CapitalExpendituresIncurredPaymentsMade
|
87000 | USD |
| CY2017 | ibio |
Capital Expenditures Incurred Payments Made
CapitalExpendituresIncurredPaymentsMade
|
71000 | USD |
| CY2017Q4 | us-gaap |
Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
|
2250000 | shares |
| CY2017Q4 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
4500000 | USD |
| CY2018Q2 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
16000000 | USD |
| CY2018 | us-gaap |
Stock Issued1
StockIssued1
|
0 | USD |
| CY2017 | us-gaap |
Stock Issued1
StockIssued1
|
12499000 | USD |
| CY2018 | us-gaap |
Interest Paid Net
InterestPaidNet
|
1917000 | USD |
| CY2017 | us-gaap |
Interest Paid Net
InterestPaidNet
|
1930000 | USD |
| CY2018Q2 | us-gaap |
Share Price
SharePrice
|
0.90 | |
| CY2017Q4 | us-gaap |
Shares Issued Price Per Share
SharesIssuedPricePerShare
|
2.00 | |
| CY2018Q3 | us-gaap |
Shares Issued Price Per Share
SharesIssuedPricePerShare
|
0.90 | |
| CY2018Q2 | ibio |
Registration Common Stock
RegistrationCommonStock
|
1500000 | USD |
| CY2018Q2 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.90 | |
| CY2018Q2 | us-gaap |
Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
|
100000 | shares |
| CY2018Q2 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
| CY2017Q4 | ibio |
Offering Price To New Investors
OfferingPriceToNewInvestors
|
0.07 | pure |
| CY2018Q2 | ibio |
Offering Price To New Investors
OfferingPriceToNewInvestors
|
0.07 | pure |
| CY2018Q2 | ibio |
Offering Price To Existing Investors
OfferingPriceToExistingInvestors
|
0.035 | pure |
| CY2017Q4 | ibio |
Offering Price To Existing Investors
OfferingPriceToExistingInvestors
|
0.035 | pure |
| CY2018Q2 | ibio |
Underwriting Discounts Commissions And Other Offering Expenses
UnderwritingDiscountsCommissionsAndOtherOfferingExpenses
|
854000 | USD |
| CY2017Q4 | ibio |
Underwriting Discounts Commissions And Other Offering Expenses
UnderwritingDiscountsCommissionsAndOtherOfferingExpenses
|
311000 | USD |
| CY2018 | us-gaap |
Profit Loss
ProfitLoss
|
-16108000 | USD |
| CY2017 | us-gaap |
Profit Loss
ProfitLoss
|
-16139000 | USD |
| CY2018 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
-1000 | USD |
| CY2017 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
0 | USD |
| CY2018 | us-gaap |
Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
|
0 | USD |
| CY2017 | us-gaap |
Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
|
0 | USD |
| CY2018 | us-gaap |
Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
|
3318000 | USD |
| CY2017 | us-gaap |
Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
|
-5178000 | USD |
| CY2018 | us-gaap |
Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
|
943000 | USD |
| CY2017 | us-gaap |
Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
|
-866000 | USD |
| CY2018 | us-gaap |
Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
|
-8000 | USD |
| CY2017 | us-gaap |
Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
|
-4000 | USD |
| CY2018 | ibio |
Current And Deferred Federal And State Taxes
CurrentAndDeferredFederalAndStateTaxes
|
4253000 | USD |
| CY2017 | ibio |
Current And Deferred Federal And State Taxes
CurrentAndDeferredFederalAndStateTaxes
|
-6048000 | USD |
| CY2018 | ibio |
Income Tax Expense Benefit Valuation Allowance
IncomeTaxExpenseBenefitValuationAllowance
|
-4253000 | USD |
| CY2017 | ibio |
Income Tax Expense Benefit Valuation Allowance
IncomeTaxExpenseBenefitValuationAllowance
|
6048000 | USD |
| CY2018 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | USD |
| CY2017 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | USD |
| CY2018Q2 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
15652000 | USD |
| CY2017Q2 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
17827000 | USD |
| CY2018Q2 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
|
2211000 | USD |
| CY2017Q2 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
|
3072000 | USD |
| CY2018Q2 | us-gaap |
Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
|
1404000 | USD |
| CY2017Q2 | us-gaap |
Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
|
1285000 | USD |
| CY2018Q2 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Loss Reserves
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves
|
1223000 | USD |
| CY2017Q2 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Loss Reserves
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves
|
2762000 | USD |
| CY2018Q2 | us-gaap |
Deferred Tax Asset Parents Basis In Discontinued Operation
DeferredTaxAssetParentsBasisInDiscontinuedOperation
|
678000 | USD |
| CY2017Q2 | us-gaap |
Deferred Tax Asset Parents Basis In Discontinued Operation
DeferredTaxAssetParentsBasisInDiscontinuedOperation
|
538000 | USD |
| CY2018Q2 | us-gaap |
Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
|
202000 | USD |
| CY2017Q2 | us-gaap |
Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
|
267000 | USD |
| CY2018Q2 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Compensated Absences
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences
|
24000 | USD |
| CY2017Q2 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Compensated Absences
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences
|
24000 | USD |
| CY2018Q2 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
20990000 | USD |
| CY2018 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.21 | pure |
| CY2017Q2 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
25241000 | USD |
| CY2018Q2 | us-gaap |
Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
|
0 | USD |
| CY2017Q2 | us-gaap |
Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
|
0 | USD |
| CY2017 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
|
1239000 | USD |
| CY2017 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.34 | pure |
| CY2018 | us-gaap |
Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
|
0.06 | pure |
| CY2017 | us-gaap |
Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
|
0.06 | pure |
| CY2018 | us-gaap |
Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
|
0.01 | pure |
| CY2017 | us-gaap |
Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
|
0.01 | pure |
| CY2018 | us-gaap |
Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
|
0 | pure |
| CY2017 | us-gaap |
Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
|
-0.05 | pure |
| CY2018 | ibio |
Effective Income Tax Rate Reconciliation Reclassification Of Incentive Stock Options To Non Qualifying Percent
EffectiveIncomeTaxRateReconciliationReclassificationOfIncentiveStockOptionsToNonQualifyingPercent
|
0 | pure |
| CY2017 | ibio |
Effective Income Tax Rate Reconciliation Reclassification Of Incentive Stock Options To Non Qualifying Percent
EffectiveIncomeTaxRateReconciliationReclassificationOfIncentiveStockOptionsToNonQualifyingPercent
|
0.13 | pure |
| CY2018 | ibio |
Effective Income Tax Rate Reconciliation Expiration Of Stock Options And Warrants Percent
EffectiveIncomeTaxRateReconciliationExpirationOfStockOptionsAndWarrantsPercent
|
-0.56 | pure |
| CY2017 | ibio |
Effective Income Tax Rate Reconciliation Expiration Of Stock Options And Warrants Percent
EffectiveIncomeTaxRateReconciliationExpirationOfStockOptionsAndWarrantsPercent
|
0 | pure |
| CY2018 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
0.28 | pure |
| CY2017 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
-0.49 | pure |
| CY2018 | ibio |
Stock Issued During Period Value Cash In Lieu For Fractional Shares
StockIssuedDuringPeriodValueCashInLieuForFractionalShares
|
-1000 | USD |
| CY2008Q2 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
|
5500000 | USD |
| CY2018Q2 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
|
66300000 | USD |
| CY2018Q2 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
|
29000000 | USD |
| CY2018Q2 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards Foreign
DeferredTaxAssetsOperatingLossCarryforwardsForeign
|
125000 | USD |
| CY2017 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
|
1.0438 | pure |
| CY2018 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
|
1.0372 | pure |
| CY2018 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P9Y | |
| CY2017 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P9Y | |
| CY2018 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
|
972000 | USD |
| us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
|
P3Y | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
|
P10Y | ||
| CY2017Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
|
P10Y | |
| CY2018Q2 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
|
319000 | USD |
| CY2018Q2 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
|
287000 | USD |
| CY2018Q2 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
|
265000 | USD |
| CY2018Q2 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
|
252000 | USD |
| CY2018Q2 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
|
237000 | USD |
| CY2018Q2 | us-gaap |
Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
|
260000 | USD |
| CY2018Q2 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
1620000 | USD |
| CY2018Q2 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
1048000 | USD |
| CY2017Q2 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
924000 | USD |
| CY2018 | ibio |
Adjustments To Additional Paid In Capital Capital Contribution
AdjustmentsToAdditionalPaidInCapitalCapitalContribution
|
1093000 | USD |
| CY2018 | us-gaap |
Noncontrolling Interest Increase From Subsidiary Equity Issuance
NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
|
1050000 | USD |
| CY2018 | us-gaap |
Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
|
0 | USD |
| CY2018 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
770000 | USD |
| CY2017 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
1010000 | USD |
| CY2017 | us-gaap |
Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
|
0 | USD |
| CY2018 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
22406000 | USD |
| CY2017 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
-170000 | USD |
| CY2018 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"><div style="font-family: "times new roman", serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Concentration of Credit Risk</div></div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"><div style="font-family: "times new roman", serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-decoration:underline;display:inline;">Cash</div></div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"><div style="font-family: "times new roman", serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company maintains principally all cash balances in one financial institution which, at times, may exceed the amount insured by the Federal Deposit Insurance Corporation. The exposure to the Company is solely dependent upon daily bank balances and the strength of the financial institution. The Company has not incurred any losses on these accounts. At June 30, 2018 and 2017, amounts in excess of insured limits were approximately $15,427,000 and $7,623,000, respectively.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> | |
| CY2018Q2 | us-gaap |
Cash Fdic Insured Amount
CashFDICInsuredAmount
|
15427000 | USD |
| CY2017Q2 | us-gaap |
Cash Fdic Insured Amount
CashFDICInsuredAmount
|
7623000 | USD |
| CY2018Q2 | us-gaap |
Shares Issued Price Per Share
SharesIssuedPricePerShare
|
0.90 | |
| CY2018Q2 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
1000 | |
| CY2018Q2 | us-gaap |
Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
|
7000000 | shares |
| CY2018Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
|
2666666 | shares |
| CY2018Q2 | us-gaap |
Conversion Of Stock Shares Converted1
ConversionOfStockSharesConverted1
|
90 | shares |
| CY2018Q3 | us-gaap |
Conversion Of Stock Shares Converted1
ConversionOfStockSharesConverted1
|
672 | shares |
| CY2018Q2 | us-gaap |
Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
|
135000 | shares |
| CY2018Q2 | us-gaap |
Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
|
On April 23, 2018, the Company held a special meeting of its stockholders at which the stockholders approved a proposal to effect an amendment to the Company's certificate of incorporation, as amended, to implement a reverse stock split at a ratio to be determined by the Company's Board of Directors in a range not less than one-for-two (1:2) and not greater than one-for-ten (1:10). | |
| CY2018Q2 | us-gaap |
Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
|
On May 23, 2018, the Company's board of directors approved the implementation of a reverse stock split at a ratio of one-for-ten (1:10) shares of the Company's Common Stock. As a result of the reverse stock split, every ten (10) shares of the Company's Common Stock either issued and outstanding or held by the Company in its treasury immediately prior to the effective time was, automatically and without any action on the part of the respective holders thereof, combined and converted into one (1) share of the Company's common stock. No fractional shares were issued in connection with the reverse stock split. Stockholders who otherwise were entitled to receive a fractional share in connection with the reverse stock split instead were eligible to receive a cash payment, which was not material in the aggregate, instead of shares. | |
| CY2018Q2 | us-gaap |
Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
|
On June 8, 2018, the Company filed a Certificate of Amendment of its Certificate of Incorporation, as amended with the Secretary of State of Delaware effecting a one-for-ten (1:10) reverse stock split of the shares of the Company's common stock, either issued and outstanding or held by the Company as treasury stock, effective as of 4:10 p.m. (Eastern Time), June 8, 2018. The Company's common stock began trading on a reverse split adjusted basis on the Exchange when the market opened Monday, June 11, 2018. | |
| CY2018Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
|
2666666 | shares |
| CY2018Q2 | us-gaap |
Share Price
SharePrice
|
0.90 | |
| CY2017Q2 | us-gaap |
Share Price
SharePrice
|
3.86 | |
| CY2016Q2 | us-gaap |
Share Price
SharePrice
|
7.20 | |
| CY2018Q2 | us-gaap |
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
|
1364583 | shares |
| CY2018 | us-gaap |
Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
|
P4Y10M24D | |
| CY2018Q2 | us-gaap |
Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
|
12.01 | |
| CY2018Q2 | us-gaap |
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
|
1144754 | shares |
| CY2018 | dei |
Entity Listing Description
EntityListingDescription
|
On June 6, 2018, the Company received notification from the NYSE American that it is not in compliance with the continued listing standards as set forth in Section 1003(a)(iii) of the NYSE American's Company Guide that, which applies if a listed company has stockholders' equity of less than $6,000,000 and has sustained losses from continuing losses and/or net losses in its five most recent fiscal years. | |
| CY2018Q2 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
16000000 | USD |
| CY2018Q2 | us-gaap |
Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
|
4350000 | shares |
| CY2018 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
14693000 | shares |
| CY2017 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
1355000 | shares |
| CY2018Q1 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
4200000 | USD |
| CY2018 | us-gaap |
Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
|
9100000 | USD |
| CY2018Q2 | ibio |
Convertible Preferred Stock Conversion Price
ConvertiblePreferredStockConversionPrice
|
0.90 | |
| CY2018 | us-gaap |
Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
|
1 | pure |
| CY2017 | us-gaap |
Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
|
0.05 | pure |
| CY2018 | us-gaap |
Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
|
38000 | USD |
| CY2017 | us-gaap |
Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
|
0 | USD |
| CY2018 | us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
0 | pure |
| CY2017 | us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
0 | pure |
